

DETAILS OF INVESTOR CALL – 6 FEBRUARY 2019

Investor call at 9.00am AEDT, Wednesday 6 February 2019 to discuss Results and Business Outlook

Adelaide, Australia, 5 February 2019: LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, announces that the Company will hold a conference call at **9.00am AEDT** on **Wednesday 6 February 2019** to discuss the Company's activities and financial results for the Quarter ended 31 December 2018 and the business outlook. The Company's CEO and Managing Director, Brent Barnes, will host the call.

How to Access the Call

To dial into the call directly, please dial in 5 to 10 minutes prior to the call time and enter the **Conference ID: 827476**. Dial in numbers are as follows:

Australian Toll Free: **1800 908 299**
 New Zealand callers: 0800 452 795
 Other callers: +61 2 9007 8048

To pre-register for the call, please follow the link below. A unique pin number will be provided for use when dialling into the call, which will bypass the operator and provide immediate access to the event.

<https://services.choruscall.com.au/diamondpass/lbt-827476-invite.html>

Accessing the Call after the event

A recording of the call will be available on the Investor Centre section of the Company's website for 60 days after the call.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beetling's- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software, and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation. LBT's third product WoundVue® is in early development; this is a proposed automated solution to assist in the management of chronic wounds.

Contacts

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com